Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Neutropenia 1Neoplasms, Plasma Cell 1Migraine Disorders 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Lymphoma 1Leukemia 1Klebsiella Infections 1Intraabdominal Infections 1Influenza, Human 1Inflammation 1Infections 1Hypokalemia 1Hypertension 1Hyperaldosteronism 1Herpes Simplex 1

Interventions

Probenecid 1Piperacillin, Tazobactam Drug Combination 1Cystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Bacterial Infections × Piperacillin, Tazobactam Drug Combination × Clear all
NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
200 enrolled

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡